Abstract: The present disclosure relates to an oral product, a process for producing the oral product, as well as to uses of said oral product. A first aspect of the oral product comprises a combination of active ingredients, wherein the combination comprises: (i) maca root or an extract thereof; (ii) a combination of B vitamins comprising at least two selected from vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12; (iii) ginseng or an extract thereof; and (iv) Coenzyme Q10, wherein the weight ratio of maca root or the extract thereof, to Coenzyme Q10, is about 50:1 to about 1:10; wherein the oral product does not include caffeine. A second aspect of the oral product comprises a combination of active ingredients, wherein the combination comprises: (i) maca root or an extract thereof; (ii) a combination of at least three B vitamins selected from vitamin B2, vitamin B6, vitamin B9 and vitamin B12; and (iii) ginseng or an extract thereof; wherein the oral product does not include caffeine.

Abstract: The present disclosure relates to an oral product, a process for producing the oral product, as well as to uses of said oral product. The oral product comprises a combination of active ingredients, wherein the combination comprises: caffeine; a combination of at least two B vitamins selected from vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, and vitamin B12; and beta-alanine.

Abstract: The present disclosure relates to an oral product, a process for producing the oral product, as well as to uses of said oral product. The oral product includes L-theanine, ginseng and lemon balm.

Abstract: The present disclosure relates to an oral product, a process for producing the oral product, as well as to uses of said oral product. The oral product comprises a combination of active ingredients, wherein the combination comprises: caffeine; a combination of B vitamins comprising at least vitamin B1, vitamin B2, vitamin B6, and vitamin B7; and L-theanine.

Abstract: The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, methods are provided for reducing eosinophils in a human in need thereof, which method comprises administering to said human a composition comprising at least one anti-IL-5 antibody, wherein at least one anti-IL-5 antibody provides a mean maximum plasma concentration of said anti-IL-5 antibody of at least about 1.03±0.21 ?g/mL, an Area Under the Curve(0-inf) value of at least about 15.5±2.7 ?g*day/mL and a serum half-life of about 16.2±2.1 days to about 21.7±2.8 days.

Abstract: The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, methods are provided for reducing eosinophils in a human in need thereof, which method comprises administering to said human a composition comprising at least one anti-IL-5 antibody, wherein at least one anti-IL-5 antibody provides a mean maximum plasma concentration of said anti-IL-5 antibody of at least about 1.03±0.21 ?g/mL, an Area Under the Curve(0-inf) value of at least about 15.5±2.7 ?g*day/mL and a serum half-life of about 16.2±2.1 days to about 21.7±2.8 days.

Abstract: The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, methods are provided for reducing eosinophils in a human in need thereof, which method comprises administering to said human a composition comprising at least one anti-IL-5 antibody, wherein at least one anti-IL-5 antibody provides a mean maximum plasma concentration of said anti-IL-5 antibody of at least about 1.03±0.21 ?g/mL, an Area Under the Curve value of at least about 15.5±2.7 ?g/day/mL and a serum half-life of about 16.2±2.1 days to about 21.7±2.8 days.

Abstract: A control device for controlling drainage of waste from a surgical stoma of a human body. The control device comprises a first cylindrical hollow body member, a drain tube extending from the first cylindrical hollow body member, a second cylindrical hollow body member rotatably coupled to the first cylindrical hollow body member and a knob configured on the second cylindrical hollow body member. The first cylindrical hollow body member comprises a skirt portion extending radially outward for being removably attached to a surface surrounding the surgical stoma of the human body. The second cylindrical hollow body member comprises an aperture configured on the second sidewall. A rotation of the knob is capable of aligning the aperture of the second cylindrical hollow body member with the drain tube of the first cylindrical hollow body member thereby forming a passage for draining the waste.

Abstract: The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, methods are provided for reducing eosinophils in a human in need thereof, which method comprises administering to said human a composition comprising at least one anti-IL-5 antibody, wherein at least one anti-IL-5 antibody provides a mean maximum plasma concentration of said anti-IL-5 antibody of at least about 1.03±0.21 ?g/mL, an Area Under the Curve value of at least about 15.5±2.7 ?g/day/mL and a serum half-life of about 16.2±2.1 days to about 21.7±2.8 days.

Abstract: A control device for controlling drainage of waste from a surgical stoma of a human body. The control device comprises a first cylindrical hollow body member, a drain tube extending from the first cylindrical hollow body member, a second cylindrical hollow body member rotatably coupled to the first cylindrical hollow body member and a knob configured on the second cylindrical hollow body member. The first cylindrical hollow body member comprises a skirt portion extending radially outward for being removably attached to a surface surrounding the surgical stoma of the human body. The second cylindrical hollow body member comprises an aperture configured on the second sidewall. A rotation of the knob is capable of aligning the aperture of the second cylindrical hollow body member with the drain tube of the first cylindrical hollow body member thereby forming a passage for draining the waste.

Abstract: A mechanism and method is presented for applying a cool object to various pressure points of the body to relieve the effects of hot flashes. In particular, the present invention involves cooling small internal sacks in a freezer, removing them when a hot flash occurs, placing the sacks in larger external pouches and then attaching the pouches to either a bracelet or watch around the wrist or a necklace such that the cool pouches can provide relief to the pressure points on the inside of the wrist, ankles or the back of the neck. Application of the cold pouches to these pressure points provides relief from the effects of hot flashes.